Analyst firms · Barclays · TVRD

Barclays TVRD price target and rating history

Tvardi Therapeutics Inc. (TVRD) · Health Care

Barclays rates Tvardi Therapeutics Inc. (TVRD) Underweight with a $3 price target, as of its latest action on Apr 20, 2026. It has published 3 rating actions on TVRD since October 2025, including 0 upgrades and 2 downgrades. Across 5 firms with a TVRD price target in the last 12 months, the median target is $9. Barclays's $3 is 67% below that.

Current rating
Underweight
Price target
$3
Median target, all firms
$9
Actions on TVRD
3

Barclays price target on TVRD

$61$32$32026
Barclays price target on TVRD, each point a stated target, October 2025 to April 2026.

Every Barclays rating on TVRD

How other firms rate TVRD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Chardan Capital MarketsBuy$8Oct 20, 2026
Piper SandlerOverweight$13Jul 8, 2026
Raymond JamesOutperform$10Jul 8, 2026
H.C. WainwrightBuy$9Jun 8, 2026
BarclaysUnderweight$3Apr 20, 2026

Questions about Barclays and TVRD

What is Barclays's price target for TVRD?
Barclays's latest stated price target for Tvardi Therapeutics Inc. (TVRD) is $3, from its action on Apr 20, 2026.
What is Barclays's rating on TVRD?
Barclays rates TVRD Underweight, a bearish rating, as of Apr 20, 2026.
When did Barclays last change its view on TVRD?
On Apr 20, 2026, Barclays downgrades to Underweight from Equal Weight, price target $3.
How does Barclays's TVRD target compare with other analysts?
Across 5 firms with a TVRD price target in the last 12 months, the median target is $9. Barclays's $3 is 67% below that.

More TVRD rating histories

All Barclays ratingsTVRD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.